{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:53:11Z","timestamp":1780437191673,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.trim.2022.101773","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:15:43Z","timestamp":1670933743000},"page":"101773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The impact of induction therapy in low-immunological risk kidney transplant recipients regardless of HLA matching"],"prefix":"10.1016","volume":"76","author":[{"given":"Maroun","family":"Abou-Jaoud\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Akiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Moussawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Abou-Jaoud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.trim.2022.101773_bb0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/ajkd.2001.26824","article-title":"Quality of life in end-stage renal disease patients","volume":"38","author":"Valderr\u00e1bano","year":"2001","journal-title":"Am. J. Kidney Dis."},{"issue":"23","key":"10.1016\/j.trim.2022.101773_bb0010","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.trim.2022.101773_bb0015","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1600-6143.2004.00535.x","article-title":"Diminishing significance of HLA matching in kidney transplantation","volume":"4","author":"Su","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.trim.2022.101773_bb0020","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.transproceed.2007.07.033","article-title":"The influence of HLA mismatches and immunosuppression on kidney graft survival: an analysis of more than 1300 patients","volume":"39","author":"Martins","year":"2007","journal-title":"Transplant. Proc."},{"issue":"Suppl. 3","key":"10.1016\/j.trim.2022.101773_bb0025","first-page":"S1","article-title":"Improving global outcomes (KDIGO) transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Disease","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.trim.2022.101773_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.ajkd.2010.04.010","article-title":"KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"56","author":"Bia","year":"2010","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.trim.2022.101773_bb0035","first-page":"CD003897","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","volume":"2010","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.trim.2022.101773_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajt.13884","article-title":"Induction therapy for kidney transplant recipients: do we still need anti-IL2 receptor monoclonal antibodies?","volume":"17","author":"Hellemans","year":"2017","journal-title":"Am. J. Transplant."},{"issue":"6","key":"10.1016\/j.trim.2022.101773_bb0045","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2215\/CJN.03800415","article-title":"Induction therapy in renal transplantation: why? what agent? what dose? we may never know","volume":"10","author":"Wiseman","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.trim.2022.101773_bb0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/TP.0b013e3181ea6788","article-title":"The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression","volume":"90","author":"Gralla","year":"2010","journal-title":"Transplantation."},{"issue":"2","key":"10.1016\/j.trim.2022.101773_bb0055","first-page":"44","article-title":"Induction therapy in half-haplotype low-risk kidney transplant patients: impact on acute rejection, graft survival, infection, and surgical complications at 3 years","volume":"7","author":"Abou-Jaoud\u00e9","year":"2019","journal-title":"Am. J. Med. Sci. Med."},{"key":"10.1016\/j.trim.2022.101773_bb0060","series-title":"Transplant International","first-page":"234","article-title":"Role of HLA mismatch in low risk kidney transplant patients without induction","volume":"Vol. 32","author":"Abou-Jaoud\u00e9","year":"2019"},{"key":"10.1016\/j.trim.2022.101773_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101490","article-title":"Effect of donor-to-recipient HLA matching in low-immunological risk kidney transplant recipients without induction therapy on acute rejection, graft survival, infections, and surgical complications at 3 years: the road towards new recommendations","volume":"69","author":"Abou-Jaoud\u00e9","year":"2021","journal-title":"Transpl. Immunol."},{"issue":"2","key":"10.1016\/j.trim.2022.101773_bb0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/tri.13079","article-title":"Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice","volume":"31","author":"Dharnidharka","year":"2018","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2022.101773_bb0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1053\/j.ajkd.2015.05.001","article-title":"US renal data system 2014 annual data report: epidemiology of kidney Disease in the United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.trim.2022.101773_bb0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/11631300-000000000-00000","article-title":"Induction therapy in renal transplant recipients: how convincing is the current evidence?","volume":"72","author":"Wagner","year":"2012","journal-title":"Drugs."},{"issue":"8","key":"10.1016\/j.trim.2022.101773_bb0105","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.transproceed.2017.06.032","article-title":"Impact of induction therapy on delayed graft function following kidney transplantation in mated kidneys","volume":"49","author":"Butler","year":"2017","journal-title":"Transplant. Proc."},{"issue":"25","key":"10.1016\/j.trim.2022.101773_bb0110","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"ELITE-symphony study. Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.trim.2022.101773_bb0115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.ajkd.2009.06.020","article-title":"Induction antibody therapy in kidney transplantation","volume":"54","author":"Padiyar","year":"2009","journal-title":"Am. J. Kidney Dis."},{"issue":"14","key":"10.1016\/j.trim.2022.101773_bb0120","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40265-014-0277-6","article-title":"New directions for rabbit antithymocyte globulin (thymoglobulin(\u00ae)) in solid organ transplants, stem cell transplants and autoimmunity","volume":"74","author":"Mohty","year":"2014","journal-title":"Drugs."},{"issue":"3","key":"10.1016\/j.trim.2022.101773_bb0125","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.transproceed.2013.03.010","article-title":"Induction therapy with basiliximab and full HLA mismatch","volume":"45","author":"Outerelo","year":"2013","journal-title":"Transplant. Proc."},{"issue":"3","key":"10.1016\/j.trim.2022.101773_bb0130","first-page":"343","article-title":"The role of HLA matching in renal transplantation: experience from one center","volume":"1","author":"Leivestad","year":"1999","journal-title":"Rev. Immunogenet."},{"issue":"4","key":"10.1016\/j.trim.2022.101773_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/j.1399-0012.2012.01654.x","article-title":"Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients","volume":"26","author":"Lim","year":"2012","journal-title":"Clin. Transpl."},{"issue":"2","key":"10.1016\/j.trim.2022.101773_bb0140","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.transproceed.2004.12.084","article-title":"Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches","volume":"37","author":"Bunnapradist","year":"2005","journal-title":"Transplant. Proc."},{"issue":"4","key":"10.1016\/j.trim.2022.101773_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1592\/phco.23.4.443.32119","article-title":"Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients","volume":"23","author":"Crompton","year":"2003","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.trim.2022.101773_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101473","article-title":"Cytomegalovirus infection in kidney transplant patients: prevalence, risk factors, and impact on outcome - a local multicentre experience","volume":"69","author":"Abou-Jaoud\u00e9","year":"2021","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.trim.2022.101773_bb0155","article-title":"Clinical and socioeconomic benefits of serological HLA-DR matching for renal transplantation over three eras of immunosuppression regimens at a single unit","volume":"233-41","author":"Taylor","year":"1993","journal-title":"Clin. Transpl."},{"issue":"1","key":"10.1016\/j.trim.2022.101773_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation."},{"issue":"3","key":"10.1016\/j.trim.2022.101773_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab triple therapy study group","volume":"338","author":"Vincenti","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.trim.2022.101773_bb0170","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2215\/CJN.08710814","article-title":"Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance","volume":"10","author":"Tanriover","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.trim.2022.101773_bb0175","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2215\/CJN.13171215","article-title":"Acute rejection rates and graft outcomes according to induction regimen among recipients of kidneys from deceased donors treated with tacrolimus and mycophenolate","volume":"11","author":"Tanriover","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:03:21Z","timestamp":1760810601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422002477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"alternative-id":["S0966327422002477"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101773","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of induction therapy in low-immunological risk kidney transplant recipients regardless of HLA matching","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101773"}}